9 citations
,
January 2015 in “Medical hypotheses” TCDD disrupts skin stem cells, causing skin issues like chloracne.
2 citations
,
January 2022 in “BioMed Research International” LED light therapy at 863 nm wavelength can slow down skin tumor growth and reduce inflammation in mice.
August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
April 2018 in “Journal of Investigative Dermatology” CENPV, a new partner of CYLD, helps regulate ciliary acetylated tubulin and is overexpressed in certain skin tumors.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
1 citations
,
August 2016 in “Journal of Investigative Dermatology” Vδ1+ T-cells in the skin contribute to hair loss in alopecia areata and could be targeted for treatment.
January 2011 in “Repository KITopen (Karlsruhe Institute of Technology)” Blocking certain proteins on immune cells may help treat alopecia areata.
12 citations
,
March 2016 in “BBA clinical” Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
2 citations
,
January 2014 in “Journal of Cytology & Histology” Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
10 citations
,
November 2023 in “Science Immunology” Super-enhancers control CD25 expression in specific cell types, affecting immune function.
1 citations
,
February 2025 in “Scientific Reports” CD4 is crucial for maintaining skin stem cell balance and aiding wound healing.
31 citations
,
February 2007 in “Molecular Carcinogenesis” Overexpressing ATF3 in mice's epithelial cells may lead to oral cancer.
March 2022 in “Benha Journal of Applied Sciences” ULBP3 levels are higher in Tinea capitis patients and may help predict the disease's severity.
April 2024 in “The Journal of experimental medicine/The journal of experimental medicine” Treg cells help repair and regenerate tissues by interacting with local cells.
84 citations
,
October 2007 in “The Journal of Immunology” Myeloid-derived suppressor cells help control autoimmune cells and promote hair regrowth in alopecia areata.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
1 citations
,
May 2025 in “The Journal of Dermatology” Increased regulatory T cell activity may lead to better outcomes in acute diffuse and total alopecia.
November 2025 in “The Journal of Immunology” BST2 is highly expressed in certain immune cells in alopecia areata, suggesting a role in the disease.
January 2025 in “Cell Communication and Signaling” CXXC5 can both suppress and promote cancer, making it a complex target for treatment.
1 citations
,
June 2022 in “Chinese medical journal/Chinese Medical Journal” Two new mutations in the CDH3 gene cause hair loss and vision problems in a young girl.
April 2023 in “Cancer research” KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.
3 citations
,
April 2023 in “Cytotechnology” 121 citations
,
December 2001 in “American Journal of Dermatopathology” TB and BCC tumors show similar follicular differentiation patterns.
21 citations
,
January 2024 in “Science Immunology” Regulatory T cells protect hair follicle stem cells by maintaining immune privilege in the skin.
September 2016 in “Journal of Dermatological Science” Plasmacytoid dendritic cells, which overproduce IFN-α, may play a crucial role in starting alopecia areata, an autoimmune disease causing hair loss.
Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
21 citations
,
May 2014 in “Toxicological Sciences” Toluene diisocyanate exposure can cause immune sensitization by interacting with proteins in hair follicles and sebaceous glands.